Combination strategies with PD-1/PD-L1 blockade: current advances and future directions.
Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. · 2022
Read Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. by Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8780712.txt.
Description
Yi and co-authors review combination strategies that pair PD-1 or PD-L1 blockade with other cancer treatments. These antibodies free T cells from an exhausted state. Ten PD-1 and three PD-L1 antibodies have won approval across cancers. Yet most patients do not respond to this therapy alone.
For most, this pathway is not the only brake on anti-tumor immunity. Pairs with chemotherapy, radiation, or targeted drugs have shown stronger results. Other partners include more immune drugs, cell transplants, and metabolic agents. Dual-function antibodies add another route. The review weighs current gains and future directions. The aim is higher response rates for more patients.
Catalog record
| CREATOR | Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 141 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |